These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
265 related items for PubMed ID: 26884069
21. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy. Li T, Huang S, Dong M, Gui Y, Wu D. Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540 [Abstract] [Full Text] [Related]
22. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer. Wang J, Cheng G, Li X, Pan Y, Qin C, Yang H, Hua L, Wang Z. Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783 [Abstract] [Full Text] [Related]
23. Down-Regulation of Nfatc1 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Prostate Cancer Cells. Liu Y, Liang T, Qiu X, Ye X, Li Z, Tian B, Yan D. Med Sci Monit; 2019 Feb 28; 25():1572-1581. PubMed ID: 30817743 [Abstract] [Full Text] [Related]
24. UHRF1 promotes cell growth and metastasis through repression of p16(ink⁴a) in colorectal cancer. Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, Zou Y, Qin HL. Ann Surg Oncol; 2012 Aug 28; 19(8):2753-62. PubMed ID: 22219067 [Abstract] [Full Text] [Related]
25. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B. PLoS One; 2013 Aug 28; 8(6):e65064. PubMed ID: 23798998 [Abstract] [Full Text] [Related]
26. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy. Li X, Huang H, Zhang J, Jiang F, Guo Y, Shi Y, Guo Z, Ao L. Prostate; 2020 Apr 28; 80(5):376-387. PubMed ID: 31961962 [Abstract] [Full Text] [Related]
27. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, Jadhav RR, Louie AD, Lin CL, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen CL, Mai S, Huang TH. Prostate; 2015 Nov 28; 75(15):1790-801. PubMed ID: 26332453 [Abstract] [Full Text] [Related]
28. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan JB, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS, Stanford JL. Clin Epigenetics; 2016 Nov 28; 8():97. PubMed ID: 27651837 [Abstract] [Full Text] [Related]
30. Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation. Wei C, Lu N, Wang L, Zhang Y, Feng Z, Yang Y, Qi F, Gu J. Oncol Rep; 2018 Jun 28; 39(6):2553-2562. PubMed ID: 29620240 [Abstract] [Full Text] [Related]
34. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. Laursen EB, Fredsøe J, Schmidt L, Strand SH, Kristensen H, Rasmussen AKI, Daugaard TF, Mouritzen P, Høyer S, Kristensen G, Stroomberg HV, Brasso K, Røder MA, Borre M, Sørensen KD. Am J Pathol; 2019 Dec 28; 189(12):2377-2388. PubMed ID: 31539518 [Abstract] [Full Text] [Related]
35. UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer. Goto D, Komeda K, Uwatoko N, Nakashima M, Koike M, Kawai K, Kodama Y, Miyazawa A, Tanaka I, Hase T, Morise M, Hasegawa Y, Kawabe T, Sato M. Cancer Invest; 2020 Apr 28; 38(4):240-249. PubMed ID: 32212938 [Abstract] [Full Text] [Related]
36. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Benko G, Spajić B, Krušlin B, Tomas D. Urol Oncol; 2013 May 28; 31(4):468-74. PubMed ID: 21514185 [Abstract] [Full Text] [Related]
37. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H, Wang J, Li T, Li Y. Clin Cancer Res; 2014 May 01; 20(9):2312-25. PubMed ID: 24610824 [Abstract] [Full Text] [Related]
38. Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer. Waldbillig F, Nitschke K, Abdelhadi A, von Hardenberg J, Nuhn P, Nientiedt M, Weis CA, Michel MS, Erben P, Worst TS. Int J Mol Sci; 2020 Jun 19; 21(12):. PubMed ID: 32575490 [Abstract] [Full Text] [Related]
39. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. Prostate; 2016 May 19; 76(6):597-608. PubMed ID: 26771938 [Abstract] [Full Text] [Related]
40. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. Stein J, Majores M, Rohde M, Lim S, Schneider S, Krappe E, Ellinger J, Dietel M, Stephan C, Jung K, Perner S, Kristiansen G, Kirfel J. Am J Pathol; 2014 Sep 19; 184(9):2430-7. PubMed ID: 25016185 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]